StockNow
Log in
U.S. Markets

Danaher (DHR) Q2 2026 (USD): EPS 1.94 (exp. 1.84), Revenue 6.3bln (exp. 6.11bln)

StockNow breaking-news AI analysis

Danaher beat Q2 expectations and raised its FY26 EPS guidance, highlighted by mid-teens bioprocessing order growth and the strongest Life Sciences performance in years, signaling a sector recovery.

News detail

Other Metrics (USD): Diagnostics Revenue 2.47bln (exp. 2.34bln) Life Sciences Revenue 1.88bln (exp. 1.8bln) Biotech Revenue 1.92bln (exp. 1.96bln) COMMENTARY:CEO Rainer Blair says Danaher delivered a better-than-expected Q2, with core growth improving versus Q1 and disciplined execution driving high-single-digit adjusted EPS growth, while Life Sciences delivered its strongest quarter in several years and bioprocessing orders grew mid-teens.GUIDANCE: Sees Q3 core revenue growth between 2.0-3.0% Y/Y, and adj. operating profit margin of about 26.5%. Raises FY26 guidance; sees FY adj. EPS between USD 8.45-8.60 (exp. 8.45; prev. saw saw 8.35-8.55)

1 stocks

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
U.S. Markets

Eli Lilly (LLY) Q2 2026 (USD): Adj. EPS 8.38 (exp. 6.01), Revenue 23bln (exp. 20.7bln)

LLYGeopolitics

Gulf official tells CNN “50:50” chance US and Iran could reach deal by Friday, CNN reports; Iranian delegation does not include IRGC, which would need to sign off on details of provisional agreement

U.S. Economy

US ADP Employment Change (Jul) 44K vs. Exp. 70K (Prev. 98K)